A Phase III trial of X-22 for smoking cessation

Trial Profile

A Phase III trial of X-22 for smoking cessation

Planning
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Nicotine (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Sponsors 22nd Century
  • Most Recent Events

    • 30 Jun 2017 New trial record
    • 22 Jun 2017 According to a 22nd Century media release, Center for Drug Evaluation and Research (CDER) of the U.S. FDA and the company will work to design this trial. The company plans to initiate this trial in first half of 2018, subject to funding source.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top